Novel P53 mutations detected by FAMA in colorectal cancers

Annals of Oncology

Volumn 17, Issue SUPPL. 7, 2006, Pages

  De Galitiis, F ^a   Cannita, K ^a   Tessitore, A ^a   Martella, F ^a   Di Rocco, Z C ^a   Russo, A ^b   Adamo, V ^c   Iacobelli, S ^d   Martinotti, S ^d   Marchetti, P ^a   Ficorella, C ^a   Ricevuto, Enrico ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Colon cancer; FAMA; Mutations; p53

Indexed keywords

DNA FRAGMENT; HETERODUPLEX; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA CLEAVAGE; EXON; FLUORESCENCE ANALYSIS; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS;

EID: 33745595079     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl957     Document Type: Article

References (33)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
2. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
3. Donehower LA. Effects of p53 mutation on tumor progression: Recent insights from mouse tumor models. Biochim Biophys Acta 1996; 1242: 171-176.
4. Diller L, Kassel J, Nelson CE et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772-5781.
5. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
6. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
7. Livingstone LR, White A, Sprouse J et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-935.
8. Kern SE, Kinzier KW, Bruskin A et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252: 1708-1711.
9. Samowitz WS, Curtin K, Ma KN et al. Prognostic significance of p53 mutations in colon cancer at the population level, Int J Cancer 2002; 99: 597-602.
10. Tortola S, Marcuello E, Gonzalez I et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999; 17: 1375-1381.
11. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 1999; 14: 1-8.
12. Soong R, Powell B, Elsaleh H et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000; 36: 2053-2060.
13. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
14. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
15. Allegra CJ, Palk S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21: 241-250.
16. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 2004; 96: 1128-1132.
17. Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol 2001; 28 (1 Suppl 1): 9-13.
18. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: How much evidence is enough? Ann Oncol 2003; 14: 1026-1038.
19. Elsaleh H, Powell B, Soontrapomchai P et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000; 58: 52-59.
20. Allegra CJ, Paik S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21: 241-250.
21. Allegra CJ, Parr AL, Wold LE et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002; 20: 1735-1743.
22. Iacopetta B, Russo A, Bazan V et al. Functional categories of TP53 mutation in colorectal cancer: Results of an international Collaborative Study. Ann Oncol 2006; Mar 8.
23. Russo A, Bazan V, Iacopetta B et al. TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23: 7518-7528.
24. Soong R, Iacopetta BJ, Harvey JM et al. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 1997; 74: 642-647.
25. Soong R, Robbins PD, Dix BR et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996; 27: 1050-1055.
26. Calzolari A, Chiarelli I, Bianchi S et al. Immunohistochemical vs. molecular biology methods. Complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997; 107:7-11.
27. Kressner U, Inganas M, Byding S et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999; 17: 593-599.
28. Kressner U, Lindmark G, Gerdin B, Pahlman L, Glimelius B. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 1996; 16: 951-957.
29. Soong R, Iacopetta BJ, Harvey JM et al. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 1997; 74: 642-647.
30. Tessitore A, Di Rocco ZC, Cannita K at al. High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis. Genes Chromosomes Cancer 2002; 35: 86-91.
31. Ricevuto E, Sobol H, Stoppa-Lyonnet D et al. Diagnostic strategy for analytical scanning of BRCA1 gene by fluorescence-assisted mismatch analysis using large, bifluorescently labeled amplicons. Clin Cancer Res 2001; 7: 1638-1646.
32. Verpy E, Biasotto M, Meo T, Tosi M. Efficient detection of point mutations on color-coded strands of target DNA. Proc Natl Acad Sci USA 1994; 91: 1873-1877.
33. Ricevuto E, Ficorella C, Fusco C et al. Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation. Am J Pathol 1996; 148: 405-413.